Second, drawing on the experience of COVID-19, there remains a difference of opinion among the major stakeholders (e.g., the World Health Organization, the US Food and Drug Administration [FDA], the National Institutes of Health [NIH], the Infectious Disease Society of America [IDSA], the Association for the Advancement of Blood and Biotherapies [AABB]) as to the role of CP, one of the major antibody-based therapies (102). This evidence concerns the gene CP and COVID-19.